However, since its activities range over so many cell types, targeting of either reduced- or enhanced-OSM signaling to specific tissues or organs, in a time sensitive fashion, would be required to enable approaches with less undesirable or unpredicted side effects. is not clear about its biology, functionin vivo,and contradictory points of view on its role in TSPAN32 certain conditions. The grouping of OSM into the family of gp130 (or IL-6/LIF) cytokines has SB 525334 been useful in rationalizing some redundant functions among SB 525334 this group and to explain lack of severe phenotypes in gene deficient mice. However, this grouping may also mask unique effects of OSM that has significant effects upon over- or underexpression in adult mammals. Reviews specifically on OSM have been published in 2003 and 2004 [1,2] and other more recent reviews of the gp130 cytokine family including those of Silver and Hunter [3] and Sims and Walsh [4] incorporate aspects of OSM biology. This review will focus on OSM, discuss its activities relevant to pathology, and examine functions of OSM that are distinct from other gp130 family members, with a view to suggest further study into this interesting molecule and SB 525334 its role in disease. == 2. Discovery, Cloning, and Expression == OSM was first purified and biochemically characterized on the basis of its antiproliferative activity on the A375 human melanoma cell linein vitro[5]. Its name was coined based on this inhibitory function on A375 and other melanoma cell lines. A potential function in the regulation of cancer was explored and further studies have clearly shown pleiotropic actions in hematopoietic, skeletal tissue alteration, metabolic, immunologic, differentiation, and inflammatory disease processes as outlined in more detail below. OSM was also found to interact with receptor complexes that included the cell signaling molecule gp130 and thus has been grouped with this gp130 family of cytokines in general. The unique full length sequence of human OSM upon molecular cloning from U937 cells was completed in 1989 [6] to determine a 2 kb mRNA transcript encoding a 252 amino acid polypeptide with a hydrophobic N-terminus signal peptide and 3AT-rich untranslated region similar to other cytokines. Although the full length SB 525334 form is active, a hydrophilic C-terminus region is SB 525334 cleaved off to yield a mature form of 196 amino acids with higher biological activity [7]. Cloning of the mouse OSM cDNA was completed in 1996 [8] and rat OSM cDNA has also been cloned [9]. The crystal structure of human OSM reveals a typical hematopoietic cytokine topology with up-up-down-down four-helix bundle with specific site 2 and site 3 epitopes predicted to interact with receptor chains on cell surfaces [1012]. Human OSM has also been found to bind to collagens I, III, and IVin vitro[13] and, while OSM maintained its bioactivity in this context, this suggests that interstitial collagens are involved in its spatial pattern of bioavailability in tissues. Individual cell populations that express OSM include activated macrophages, monocytes, T cells, and dendritic cells [5,6,14] (reviewed in [1]) although it is not clear if specific subsets of T cells differentially express OSM. Grenier et al. [15] showed that OSM could be released by neutrophils from preformed stores and these cells could also synthesize OSM upon stimulation by LPS or GM-CSF. OSM was also shown to be released by neutrophils from patients with acute lung injury [16]. Enhanced levels of OSM could be detected systemically in septic shock [17] and early (day 1) in patients with overt bacterial peritonitis [18]. Monocyte/macrophages, a primary source of OSM, release OSM upon stimulation with agents such as TLR-ligands or prostaglandins [19]. Generally OSM systemic levels are low in chronic inflammatory conditions and levels at local sites of inflammation are more indicative of potential function in chronic disease (see below). OSM expression during mouse development was noted in hematopoietic cells of developing.